Yet another bispecific, humanized IgG1 antibody which is beneath investigation is zenocutuzumab (MCLA-128), which acts via two unbiased mechanisms of motion: inhibition of HER2–HER3 signalling and elimination of tumour cells via ADCC. MCLA-128 capabilities by using a ‘dock and block’ system whereby a single arm of your antibody binds HER2 https://www.directivepublications.org/journal-of-clinical-breast-cancer/